Valion Bio (VBIO) Receivables - Net (2021 - 2025)

Valion Bio has reported Receivables - Net for 5 years, with the latest figure at $19000.0 in Q3 2025.

• On a quarterly basis, Receivables - Net rose 111.11% year-over-year to $19000.0 in Q3 2025; TTM through Sep 2025 was $19000.0, a 111.11% increase from a year earlier, with the FY2024 full-year figure at $69000.0, down 60.34% from the prior year.
• Receivables - Net was $19000.0 for Q3 2025 at Valion Bio, up from $13000.0 in the prior quarter.
• The five-year high for Receivables - Net was $174000.0 in Q4 2023, with the low at $9000.0 in Q3 2024.
• Average Receivables - Net over 5 years is $68187.5, with a median of $71500.0 recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Receivables - Net sank 93.13% in 2024, then surged 111.11% in 2025.
• Over 5 years, Receivables - Net stood at $92000.0 in 2021, then advanced by 16.3% to $107000.0 in 2022, then soared by 62.62% to $174000.0 in 2023, then sank by 60.34% to $69000.0 in 2024, then slumped by 72.46% to $19000.0 in 2025.
• The last three Receivables - Net figures came in at $19000.0 (Q3 2025), $13000.0 (Q2 2025), and $13000.0 (Q1 2025), per Business Quant data.